Ernexa Therapeutics Inc. (ERNA) Net Margin (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly Net Margin came in at 30352.63% in Q4 2024, down 1777916.0% YoY from N/an in Q1 2024, and down 455.62% on a QoQ basis from 5462.83% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) Net Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 13 years of Net Margin data on file, last reported at 30352.63% in Q4 2024.
- Quarterly Net Margin fell 1777916.0% year-over-year to 30352.63% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 7425.83% (up 1425817.0% YoY) and the FY2024 annual result came in at 7425.83%, up 1425817.0% from the prior year.
- Net Margin declined to 30352.63% in Q4 2024, from 5462.83% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 50.88% in Q1 2020 to a low of 30352.63% in Q4 2024.
- A 3-year average of 9516.84% and a median of 10962.75% in 2023 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 549991 bps in 2024, down 1777916 bps in 2024.
- Tracing ERNA's Net Margin over 3 years: stood at 188.78% in 2020, then sank by 6560 bps to 12573.47% in 2023, then sank by 141 bps to 30352.63% in 2024.
- The last three Net Margin figures came in at 30352.63% (Q4 2024), 5462.83% (Q3 2024), and 11780.85% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -30,352.63% |
| Sep 30, 2024 | -5,462.83% |
| Jun 30, 2024 | -11,780.85% |
| Mar 31, 2024 | -14,142.55% |
| Dec 31, 2023 | -12,573.47% |
| Sep 30, 2023 | -10,962.75% |
| Dec 31, 2020 | -188.78% |
| Sep 30, 2020 | -136.77% |
| Mar 31, 2020 | -50.88% |
| Dec 31, 2019 | -25.17% |
| Sep 30, 2019 | -7.66% |
| Jun 30, 2019 | -1.88% |
| Mar 31, 2019 | -6.48% |
| Dec 31, 2018 | 0.74% |
| Sep 30, 2018 | 3.70% |
| Jun 30, 2018 | -2.19% |
| Mar 31, 2018 | -7.10% |
| Dec 31, 2017 | -10.54% |
| Sep 30, 2017 | -3.54% |
| Jun 30, 2017 | -2.96% |